NO953781L - Terapeutisk anvendelse av keratinocyttvekstfaktor - Google Patents

Terapeutisk anvendelse av keratinocyttvekstfaktor

Info

Publication number
NO953781L
NO953781L NO953781A NO953781A NO953781L NO 953781 L NO953781 L NO 953781L NO 953781 A NO953781 A NO 953781A NO 953781 A NO953781 A NO 953781A NO 953781 L NO953781 L NO 953781L
Authority
NO
Norway
Prior art keywords
growth factor
therapeutic application
kgf
keratinocyte growth
vivo
Prior art date
Application number
NO953781A
Other languages
English (en)
Norwegian (no)
Other versions
NO953781D0 (no
Inventor
Glenn F Pierce
Regina M Housley
Charles F Morris
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO953781(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO953781D0 publication Critical patent/NO953781D0/no
Publication of NO953781L publication Critical patent/NO953781L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
NO953781A 1993-03-26 1995-09-25 Terapeutisk anvendelse av keratinocyttvekstfaktor NO953781L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4074293A 1993-03-26 1993-03-26
PCT/US1994/003208 WO1994023032A1 (en) 1993-03-26 1994-03-24 Therapeutic uses of keratinocyte growth factor

Publications (2)

Publication Number Publication Date
NO953781D0 NO953781D0 (no) 1995-09-25
NO953781L true NO953781L (no) 1995-11-27

Family

ID=21912689

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953781A NO953781L (no) 1993-03-26 1995-09-25 Terapeutisk anvendelse av keratinocyttvekstfaktor

Country Status (23)

Country Link
EP (1) EP0619370B1 (de)
JP (1) JP3578761B2 (de)
KR (1) KR100390340B1 (de)
CN (1) CN1064710C (de)
AT (1) ATE183233T1 (de)
AU (1) AU707340B2 (de)
CA (1) CA2159109C (de)
CZ (1) CZ285996B6 (de)
DE (1) DE69419958T2 (de)
DK (1) DK0619370T3 (de)
ES (1) ES2136673T3 (de)
FI (1) FI954541L (de)
GR (1) GR3031509T3 (de)
HU (1) HU220641B1 (de)
IL (4) IL137581A (de)
NO (1) NO953781L (de)
NZ (1) NZ263967A (de)
RU (1) RU2146148C1 (de)
SG (1) SG49841A1 (de)
SI (1) SI0619370T1 (de)
SK (1) SK281674B6 (de)
UA (1) UA46706C2 (de)
WO (1) WO1994023032A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
WO1996011949A2 (en) * 1994-10-13 1996-04-25 Amgen Inc. Analogs of keratinocyte growth factor
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
WO1996025422A1 (en) * 1995-02-14 1996-08-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
PT871730E (pt) * 1995-10-11 2004-11-30 Chiron Corp Combinacao de pdgf, kgf, igf e igfbp para cicatrizacao de ferimentos
GB9619660D0 (en) * 1996-09-20 1996-11-06 Scient Hospital Suppl Int Ltd Prevention of gastrointestinal damage
SI0941110T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Uses of keratinocyte growth factor-2
WO1998016243A1 (en) * 1996-10-15 1998-04-23 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6228839B1 (en) * 1997-12-19 2001-05-08 Emory University Use of keratinocyte growth factor to improve oxidative status
WO1999032135A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6599879B1 (en) 1998-02-13 2003-07-29 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
WO2001070255A2 (en) 2000-03-20 2001-09-27 Pfizer Products, Inc. Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
CN1491231A (zh) * 2001-02-06 2004-04-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰角质形成细胞生长因子(kgf)
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
RU2243784C2 (ru) * 2003-02-25 2005-01-10 Козлов Владимир Александрович Способ лечения больных хроническим гепатитом
EP1789138A2 (de) * 2004-09-13 2007-05-30 University Of Southampton Wachstumsfaktorbehandlung bei asthma
RU2391990C1 (ru) * 2008-11-25 2010-06-20 Александр Сергеевич Ботин Композиция для стимулирования роста и регенерации клеток, (варианты), а также способ ее получения (варианты)
CN101822821B (zh) * 2010-04-27 2013-01-23 复旦大学附属中山医院 角质细胞生长因子-2在制备防治肺损伤的药物中的应用
CN104707164B (zh) * 2015-03-31 2017-01-18 中国人民解放军军事医学科学院基础医学研究所 一种复合壳聚糖水凝胶敷料及其制备方法和应用
CN106226511B (zh) * 2016-07-28 2018-04-06 苏州金盟生物技术有限公司 一种重组人角质细胞生长因子生物学活性检测方法
CN107753932A (zh) * 2016-08-22 2018-03-06 中国辐射防护研究院 Kgf在制备治疗或预防放射性肠炎药物中的用途
JP7135106B2 (ja) 2018-11-27 2022-09-12 株式会社海月研究所 頭皮頭髪用組成物
KR20210114646A (ko) * 2020-03-11 2021-09-24 (주)메디코스바이오텍 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2250213C2 (ru) * 1989-01-31 2005-04-20 Джеффри С. РУБИН Выделенный белок фактора роста кератиноцита (kgf), рекомбинантная молекула днк, вектор, способ конструирования клетки-хозяина, способ получения белка, фармацевтическая композиция
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのgm―csf及びg―csfの使用

Also Published As

Publication number Publication date
CZ285996B6 (cs) 1999-12-15
HU220641B1 (hu) 2002-03-28
KR100390340B1 (ko) 2003-09-26
NZ263967A (en) 2005-02-25
UA46706C2 (uk) 2002-06-17
CA2159109A1 (en) 1994-10-13
CN1064710C (zh) 2001-04-18
KR960701204A (ko) 1996-02-24
FI954541A7 (fi) 1995-11-23
SK281674B6 (sk) 2001-06-11
HUT72711A (en) 1996-05-28
CZ248295A3 (en) 1996-12-11
JP2002526026A (ja) 2002-08-13
AU6524394A (en) 1994-10-24
ES2136673T3 (es) 1999-12-01
JP3578761B2 (ja) 2004-10-20
DK0619370T3 (da) 2000-02-28
DE69419958T2 (de) 2000-04-20
AU707340B2 (en) 1999-07-08
RU2146148C1 (ru) 2000-03-10
GR3031509T3 (en) 2000-01-31
DE69419958D1 (de) 1999-09-16
HU9502800D0 (en) 1995-12-28
CA2159109C (en) 2004-11-16
IL109122A0 (en) 1994-06-24
IL109122A (en) 2004-07-25
EP0619370B1 (de) 1999-08-11
FI954541A0 (fi) 1995-09-25
WO1994023032A1 (en) 1994-10-13
FI954541L (fi) 1995-11-23
IL137581A0 (en) 2001-07-24
IL161568A0 (en) 2004-09-27
IL137581A (en) 2009-09-01
ATE183233T1 (de) 1999-08-15
SI0619370T1 (en) 1999-10-31
EP0619370A1 (de) 1994-10-12
NO953781D0 (no) 1995-09-25
SG49841A1 (en) 1998-06-15
SK118595A3 (en) 1996-11-06
CN1217022A (zh) 1999-05-19

Similar Documents

Publication Publication Date Title
NO953781L (no) Terapeutisk anvendelse av keratinocyttvekstfaktor
BORA JR et al. Inhibitors of collagen biosynthesis as a means of controlling scar formation in tendon injury
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DK1007566T3 (da) Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf
Laato et al. Effect of epidermal growth factor (EGF) on experimental granulation tissue
DE69738336D1 (de) Verwendung von keratinocyte growth factor-2
DE69328527D1 (de) Carboxypeptidase-ähnliches Protein aus Knochen und Verfahren zur dessen Herstellung
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
ATE428438T1 (de) Tcf-ii enthaltende medizinische zusammensetzung
ES2167322T3 (es) Proteina de tipo cadherinico relacionada con los huesos y procedimiento para su preparacion.
Zhao et al. Autoradiographic localization of endothelin-1 binding sites in porcine skin
Jalil The Influence of Anisotropic Tissue Expander on Nestin and Trkb Expression in Rat Cranio-facial Region.
Jain et al. Evaluation of Wound Healing Activity of Herbal Formulation
Bush The Effects of Wound Mechanical Factors and Intradermal Transforming Growth Factor β3 Application on the Outcome of Cutaneous Scars
Tabata Regenerative Medical Therapy for Hard Tissues Based on Tissue Engineering

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application